a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. We have successfully utilized the platform to date to identify oral, GI-restricted peptides (PTG-100 and PTG-200) for inflammatory bowel diseases (IBD) ...
a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. We have successfully utilized the platform to date to identify oral, GI-restricted peptides (PTG-100 and PTG-200) for inflammatory bowel diseases (IBD) and injectable peptides (PTG-300) for rare blood disorders.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.